veludacigib   Click here for help

GtoPdb Ligand ID: 12625

Synonyms: BAY 2965501 | BAY-2965501 | BAY2965501
Compound class: Synthetic organic
Comment: BAY 2965501 is a potential first-in-class inhibitor of the atypical protein kinase C isoform protein kinase C zeta (PKCζ). It was developed for anti-tumour potential. The chemical structure was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 (Orlando) meeting of the AACR.
The chemical structure of BAY 2965501 is identical to that for the INN veludacigib (proposed list 132, Feb. 2025).
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 136.31
Molecular weight 414.46
XLogP 1.01
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@H](C(=O)N)N(C1=CC=C(C=C1)F)C2=NC(=C(C(=O)C3=CC=C(C=C3)OC)S2)N
Isomeric SMILES COC1=CC=C(C=C1)C(=O)C2=C(N)N=C(S2)N([C@H](C)C(N)=O)C3=CC=C(F)C=C3
InChI InChI=1S/C20H19FN4O3S/c1-11(19(23)27)25(14-7-5-13(21)6-8-14)20-24-18(22)17(29-20)16(26)12-3-9-15(28-2)10-4-12/h3-11H,22H2,1-2H3,(H2,23,27)/t11-/m1/s1
InChI Key HSBUVKDEUUJREZ-LLVKDONJSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
BAY 2965501 has progressed to early stage clinical evaluation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05614102 A First-in-human Study to Learn How Safe the Study Treatment BAY2965501 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors Phase 1 Interventional Bayer